Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.2
Journals
Thalassemia Reports
Special Issues
Innovative Therapies and Management of Complications in Hemoglobinopathies
share announcement

Innovative Therapies and Management of Complications in Hemoglobinopathies

A special issue of Thalassemia Reports (ISSN 2039-4365). This special issue belongs to the section "Innovative Treatment of Thalassemia".

Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 2433

Special Issue Editors

Dr. Sophia Delicou

E-Mail
Guest Editor
Thalassemia and Sickle Cell Disease Unit, Expertise Center of Hemoglobinopathies and Their Complications, Hippokration General Hospital of Athens, 11527 Athens, Greece
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections; molecular issues of haemo-globinopathies; adverse reactions and other complications of transfusiondpendent thalassaemia; patient blood management; blood donor management; pathogen reduction technologies; transfusion transmitted infections
Prof. Dr. Constantina Politis

E-Mail
Guest Editor
Coordinating Haemovigilance Centre and Surveillance of Transfusion, Hellenic National Public Health Organisation, Athens, Greece
Interests: transfusion medicine; clinical practices; quality and safety issues; regulatory issues; transfusion education for medical and nursing staff; haemovigilance; epidemiology; blood transfusion in the context of thalassaemia and sickle cell disease; molecular issues of haemoglobinopathies; adverse reactions and other complications of transfusion-dependent thalassaemia; patient blood management; risk management: an important tool for improving quality; blood donor management; pathogen reduction technologies; pathogen inactivation technologies; transfusion transmitted infections; surveillance for substances of human origin (SoHOs): blood, tissues, cells, medically assisted reproduction
Dr. Aikaterini Xydaki

E-Mail
Guest Editor Assistant
Thalassemia and Sickle Cell Unit, Expertise Center of Hemoglobinopathies and Their Complications, Hippocration General Hospital, GR-11527 Athens, Greece
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections
Dr. Maria Moraki

E-Mail
Guest Editor Assistant
Thalassemia and Sickle Cell Unit, Expertise Center of Hemoglobinopathies and Their Complications, Hippocration General Hospital, GR-11527 Athens, Greece
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections; pediatrics

Special Issue Information

Dear Colleagues,

Hemoglobinopathies, such as thalassemia and sickle cell disease, are common genetic disorders that constitute a major healthcare challenge worldwide. Advances in treatments and management strategies, particularly for complications such as transfusional iron overload and secondary iron overload, have improved patient outcomes. However, gaps remain in the management of emerging complications, including hepatocellular carcinoma, cardiovascular issues, and alloimmunization. The aim of this Special Issue is to explore cutting-edge therapies encompassing gene therapy, innovative iron chelation, and pharmacological approaches to improve the management of hemoglobinopathies.

This Special Issue will concentrate on comprehensive strategies for the management of transfusion-related complications and chronic issues that arise, with a focus on long-term patient survival. These will also include multidisciplinary care, early recognition of complications, and improving the safety of blood transfusions. Topics of interest comprise novel therapeutic interventions, long-term monitoring of iron overload, and personalized transfusion protocols to optimize patient outcomes.

Aimed at hematologists, clinical researchers, and allied health professionals, this Special Issue invites original research, systematic reviews, and case reports that bridge the gap between clinical practice and advanced research. It aims to advance knowledge and standards of care for patients with hemoglobinopathies, with an emphasis on improving quality of life and innovative, patient-centered management.

Dr. Sophia Delicou
Prof. Dr. Constantina Politis
Guest Editors

Dr. Aikaterini Xydaki
Dr. Maria Moraki
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Thalassemia Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hemoglobinopathies
  • thalassemia
  • sickle cell disease
  • transfusion medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

21 pages, 3070 KiB  
Systematic Review
Curcumin Therapy Reduces Iron Overload and Oxidative Stress in Beta-Thalassemia: Findings from a Meta-Analytic Study
by Kabelo Mokgalaboni, Wendy N. Phoswa, Perpetua Modjadji and Sogolo L. Lebelo
Thalass. Rep. 2025, 15(3), 7; https://doi.org/10.3390/thalassrep15030007 - 2 Jul 2025
Viewed by 353
Abstract
The risk of anemia and iron overload is a global concern in beta (β)-thalassemia. The β-thalassemia primary treatment includes blood transfusion and iron chelation therapy; however, both are associated with risks such as anemia, iron depletion, overload, and oxidative stress if not adequately [...] Read more.
The risk of anemia and iron overload is a global concern in beta (β)-thalassemia. The β-thalassemia primary treatment includes blood transfusion and iron chelation therapy; however, both are associated with risks such as anemia, iron depletion, overload, and oxidative stress if not adequately monitored. Therefore, this study investigates the effects of curcumin on anemia, iron overload, and oxidative stress in β-thalassemia. In this meta-analysis, search terms including “curcumin,” “Curcuma longa,” “curcuminoids,” “turmeric,” and “thalassemia” were used in Scopus and PubMed to identify studies published from inception to 15 February 2025. The quantitative analysis was performed using a meta-analysis web tool, and the effect estimates were reported as the mean difference (MD) or standardized mean difference (SMD), along with 95% confidence intervals (CI). Our analysis showed no significant effect on hemoglobin (p = 0.1788) and red blood cell count (p = 0.9534). In contrast, there was a significant decrease in serum ferritin [SMD = −0.24 (−0.46, −0.02), p = 0.0335], non–transferrin bound iron (NTBI), [SMD = −0.59 (−0.98, −0.19), p = 0.0039] and serum iron, [SMD = −0.30 (−0.60, −0.01), p = 0.0425]. Furthermore, there was a reduction in reactive oxygen species; [SMD = −0.83 (−1.23, −0.44), p < 0.0001] and malonaldehydes, [MD = −343.85 nmol/g Hb (−465.94, −221.76), p < 0.0001]. A dose of 500 mg of curcumin was found to be more effective in reducing the NTBI. The findings suggest that curcumin may help reduce iron overload and oxidative stress in β-thalassemia; however, its effect on improving anemia appears to be limited. Given the small sample size of the included studies, we recommend that future research involve larger cohorts and employ rigorous methodologies to evaluate the therapeutic potential of curcumin in β-thalassemia thoroughly. Additionally, we recommend using curcumin-enhancing strategies to improve its bioavailability and administer an optimal yet effective dose. Full article
(This article belongs to the Special Issue Innovative Therapies and Management of Complications in Hemoglobinopathies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop